Circulating tumor cells in neuroblastoma: Current status and future perspectives

Yang, Ran; Zheng, Shan; Dong, Rui

doi:10.1002/cam4.4893

Cited by 10 publications

(5 citation statements)

References 108 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike cell-free DNA or RNA, CTCs are short-lived tumor cells shed from primary or metastatic sites that contain comprehensive information on tumor status. CTCs thus are dynamic markers whose presence in blood could provide actionable information to guide neuroblastoma patient management ( 64 ). Using CCT2 as a marker for CTCs adds pertinent information on the potential for the detected CTCs to originate from an aggressive or invasive cancer.…”

Section: Discussionmentioning

confidence: 99%

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

et al. 2022

View full text Add to dashboard Cite

Chaperonin containing TCP1 (CCT/TRiC) is a multi-subunit protein folding complex that enables the cancer phenotype to emerge from the mutational landscape that drives oncogenesis. We and others linked increased expression of CCT subunits to advanced tumor stage and invasiveness that inversely correlates with cancer patient outcomes. In this study, we examined the expression of the second CCT subunit, CCT2, using genomic databases of adult and pediatric tumors and normal tissues, and found that it was highly expressed in pediatric cancers, showing a significant difference compared to normal tissues. Histologic staining confirmed that CCT subunits are highly expressed in tumor tissues, which was exemplified in neuroblastoma. Using two neuroblastoma cells, MYCN-amplified, IMR-32 cells, and non-amplified, SK-N-AS cells, we assessed baseline levels for CCT subunits and found expressions comparable to the highly invasive triple-negative breast cancer (TNBC) cell line, MDA-MB-231. Exogenous expression of CCT2 in both SK-N-AS and IMR-32 cells resulted in morphological changes, such as larger cell size and increased adherence, with significant increases in the CCT substrates, actin, and tubulin, as well as increased migration. Depletion of CCT2 reversed these effects and reduced cell viability. We evaluated CCT as a therapeutic target in IMR-32 cells by testing a novel peptide CCT inhibitor, CT20p. Treatment with CT20p induced cell death in these neuroblastoma cells. The use of CCT2 as a biological indicator for detection of neuroblastoma cells shed in blood was examined by spiking IMR-32 cells into human blood and using an anti-CCT2 antibody for the identification of spiked cancer cells with the CellSearch system. Results showed that using CCT2 for the detection of neuroblastoma cells in blood was more effective than the conventional approach of using epithelial markers like cytokeratins. CCT2 plays an essential role in promoting the invasive capacity of neuroblastoma cells and Frontiers in Oncology frontiersin.org 01

show abstract

Section: Discussionmentioning

confidence: 99%

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Compared to adult solid tumors, neuroblastoma has fewer mutations, which presents a unique advantage. Moreover, it is possible to use single-cell and CTC proteomics analysis, which may lead us to a new step attributable to the capacity to detect cells more likely to resist treatment ( 54 ).…”

Section: Future Perspectivesmentioning

confidence: 99%

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review

Alpuim Costa,

Gonçalves-Nobre,

Sampaio-Alves

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Neuroblastoma is the most frequently diagnosed cancer during the first year of life. This neoplasm originates from neural crest cells derived from the sympathetic nervous system, adrenal medulla, or paraspinal ganglia. The clinical presentation can vary from an asymptomatic mass to symptoms resulting from local invasion and/or spread of distant disease spread. The natural history of neuroblastoma is highly variable, ranging from relatively indolent biological behavior to a high-risk clinical phenotype with a dismal prognosis. Age, stage, and biological features are important prognostic risk stratification and treatment assignment prognostic factors. The multimodal therapy approach includes myeloablative chemotherapy, radiotherapy, immunotherapy, and aggressive surgical resection. Hyperbaric oxygen therapy (HBOT) has been proposed as a complementary measure to overcome tumor hypoxia, which is considered one of the hallmarks of this cancer treatment resistance. This article aims to review the relevant literature on the neuroblastoma pathophysiology, clinical presentation, and different biological and genetic profiles, and to discuss its management, focusing on HBOT.

show abstract

“…CTCs can appear as individual cells or clusters, with the latter being associated with a higher metastasis potential [28]. Various methods have been developed to detect CTCs [29], including immunocytochemical methods [30], fluorescence-activated cell sorting (FACS) [31], reverse transcription-quantitative polymerase chain reaction [32], fluorescence in situ hybridization (FISH) [33], and mass spectrometry [27]. Nonetheless, the main challenge of CTC liquid biopsy is based on the scarce number of CTCs in circulation, i.e., patients with advanced metastasis show up to 10 CTCs per 1 mL of peripheral blood [28].…”

Section: Introductionmentioning

confidence: 99%

“…[ [27][28][29][31][32][33] Circulating tumor DNA (ctDNA) ctDNA is shed by primary tumor cells and subsequently enters the bloodstream. As such, ctDNA carries the genetic alterations present in the original tumor.…”

mentioning

confidence: 99%

Extracellular Vesicles for Childhood Cancer Liquid Biopsy

Singhto,

Pongphitcha,

Jinawath

et al. 2024

Cancers

View full text Add to dashboard Cite

Liquid biopsy involves the utilization of minimally invasive or noninvasive techniques to detect biomarkers in biofluids for disease diagnosis, monitoring, or guiding treatments. This approach is promising for the early diagnosis of childhood cancer, especially for brain tumors, where tissue biopsies are more challenging and cause late detection. Extracellular vesicles offer several characteristics that make them ideal resources for childhood cancer liquid biopsy. Extracellular vesicles are nanosized particles, primarily secreted by all cell types into body fluids such as blood and urine, and contain molecular cargos, i.e., lipids, proteins, and nucleic acids of original cells. Notably, the lipid bilayer-enclosed structure of extracellular vesicles protects their cargos from enzymatic degradation in the extracellular milieu. Proteins and nucleic acids of extracellular vesicles represent genetic alterations and molecular profiles of childhood cancer, thus serving as promising resources for precision medicine in cancer diagnosis, treatment monitoring, and prognosis prediction. This review evaluates the recent progress of extracellular vesicles as a liquid biopsy platform for various types of childhood cancer, discusses the mechanistic roles of molecular cargos in carcinogenesis and metastasis, and provides perspectives on extracellular vesicle-guided therapeutic intervention. Extracellular vesicle-based liquid biopsy for childhood cancer may ultimately contribute to improving patient outcomes.

show abstract

Circulating tumor cells in neuroblastoma: Current status and future perspectives

Cited by 10 publications

References 108 publications

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review

Extracellular Vesicles for Childhood Cancer Liquid Biopsy

Contact Info

Product

Resources

About